NCT03961971View on ClinicalTrials.gov

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

November 16, 2022

Study Completion Date

September 30, 2026

Conditions
Glioblastoma Multiforme
Interventions
DRUG

MBG453

Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Trial Locations (2)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

94305

Stanford University, Stanford

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER